Jin S. Im
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (2)
Purpose: The aim of this study is to determine immune-related biomarkers to predict effective antitumor immunity in myelodysplastic syndrome (MDS) during immunotherapy (IMT, αCTLA-4, and/or αPD-1 antibodies) and/or hypomethylating agent (HMA). Experimental Design: Peripheral blood samples from 55 patients with MDS were assessed for immune subsets, T-cell receptor (TCR) repertoire, mutations in 295 acute myeloid leukemia (AML)/MDS-related genes, and immune-related gene expression profiling before and after the first treatment. Results: Clinical responders treated with IMT ± HMA but not HMA alone showed a significant expansion of central memory (CM) CD8 + T cells, diverse TCRβ repertoire pretreatment with increased clonality and emergence of novel clones after the initial treatment, and a higher mutation burden pretreatment with subsequent reduction posttreatment. Autophagy, TGFβ, and Th1 differentiation pathways were the most downregulated in nonresponders after treatment, while upregulated in responders. Finally, CTLA-4 but not PD-1 blockade attributed to favorable changes in immune landscape. Conclusions: Analysis of tumor–immune landscape in MDS during immunotherapy provides clinical response biomarkers.
Year:
2025
Purpose: The aim of this study is to determine immune-related biomarkers to predict effective antitumor immunity in myelodysplastic syndrome (MDS) during immunotherapy (IMT, αCTLA-4, and/or αPD-1 antibodies) and/or hypomethylating agent (HMA). Experimental Design: Peripheral blood samples from 55 patients with MDS were assessed for immune subsets, T-cell receptor (TCR) repertoire, mutations in 295 acute myeloid leukemia (AML)/MDS-related genes, and immune-related gene expression profiling before and after the first treatment. Results: Clinical responders treated with IMT ± HMA but not HMA alone showed a significant expansion of central memory (CM) CD8+ T cells, diverse TCRβ repertoire pretreatment with increased clonality and emergence of novel clones after the initial treatment, and a higher mutation burden pretreatment with subsequent reduction posttreatment. Autophagy, TGFβ, and Th1 differentiation pathways were the most downregulated in nonresponders after treatment, while upregulated in responders. Finally, CTLA-4 but not PD-1 blockade attributed to favorable changes in immune landscape. Conclusions: Analysis of tumor–immune landscape in MDS during immunotherapy provides clinical response biomarkers.
Year:
2023
Collaborators (9)
Dinler Antunes
Assistant Professor of Computational Biology
University of Houston
Hussein A. Abbas
The University of Texas MD Anderson Cancer Center
Sung-Eun Lee
-
Maison Grefe
-
Andrew Futreal
Chair and Professor
The University of Texas MD Anderson Cancer Center
Koichi Takahashi
The University of Texas MD Anderson Cancer Center
Gheath Alatrash
Professor
The University of Texas MD Anderson Cancer Center
Guillermo Garcia-Manero
The University of Texas MD Anderson Cancer Center
Naval G. Daver
Professor of Medicine
The University of Texas MD Anderson Cancer Center
Make your next move.
Prepare your application
Review drafts before you send them.